NCT04628143View on ClinicalTrials.gov

A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

December 21, 2020

Primary Completion Date

April 5, 2021

Study Completion Date

April 5, 2021

Conditions
COVID-19
Interventions
DRUG

Nafamostat Mesilate

Administered intravenously as a continuous infusion

Trial Locations (1)

Unknown

Korea Cancer Center Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT04628143 - A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia | Biotech Hunter | Biotech Hunter